A Phase 2 Study of Tarceva for Untreated, Good Prognosis Patients With Advanced Non-Small Cell Lung Cancer
PHASE2CompletedINTERVENTIONAL
Enrollment
40
Participants
Timeline
Start Date
June 30, 2004
Primary Completion Date
March 31, 2012
Study Completion Date
March 31, 2012
Conditions
Lung Cancer
Interventions
DRUG
Erlotinib (Tarceva)
Erlotinib
Trial Locations (1)
84112
University of Utah, Salt Lake City
All Listed Sponsors
lead
University of Utah
OTHER
NCT00585533 - A Phase 2 Study of Tarceva for Untreated, Good Prognosis Patients With Advanced Non-Small Cell Lung Cancer | Biotech Hunter | Biotech Hunter